Drug Development Market: Biosimulation Technology & Nanoparticles Analyzed in New Market Research Reports at ReportsnReports.com
Global biosimulation market is expected to reach $1.2 billion by 2017. A new report helps investigate innovation in the clinical drug development arena, documenting modeling and simulation based approaches to improving efficiency, as well as novel clinical trial designs.
Dallas, Texas (PRWEB) October 25, 2012
Biosimulation in preclinical and clinical stages contributed maximum share (60%) to the global biosimulation market in 2011. North America is the biggest market for biosimulation followed by Europe. North America, which is the largest drug market in the world contributes one third for the global biosimulation market. Europe is the fastest growing market for biosimulation the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and development. Asian market is still considered to be in development stages because of non availability of skilled workforce and infrastructure in place.
The report “Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)” will analyze the potential of biosimulation in drug discovery and development. Biosimulation is used across the drug discovery and development program (such as target identification, target validation, lead discovery, lead optimization, preclinical and clinical test). The major driving factor for this market is the cost and time spent on drug discovery and development programs and failure of drug candidates in the late development stages. Pharmaceutical companies around the globe spent around $68 billion in 2011 in drug discovery and development programs, many of the drug discovery and development programs fail in the late stages of the clinical trials, wasting all the years of efforts and money. There is a need for predictive technology which would outlay the outcome of a drug candidate in the discovery stages; biosimulation is one such technology which can bring down the cost on drug discovery and development programmes by focusing on promising lead drug candidates and experiments.
Scope of the Report
On the basis of Applications: The biosimulation market is segmented on the basis of its application in drug discovery and development processes such as: Target identification and validation, lead discovery, optimization, preclinical and clinical trials. Each application is further described in detail in the report with volume and revenue forecasted for each application.
On the basis of Geography: North America, Europe, Asia and ROW.
The report profiles leading players of this industry with their recent developments and other strategic industry activities. These include: Accelrys (U.S.), Schrodinger (U.S.), Certara (U.S.), Simulation plus (U.S.), Rhenovia (France), ACD/Labs (Canada), CCG (Canada), LeadScope (U.S.), Entelos (U.S.), Genedata (Switzerland), Physiomics (U.K.), Insilico biotechnology (Germany), Insilico biosciences (U.S.), Archimedes (U.S.), Compugen (Israel).
Another market research and analysis report shows that collaboration and open innovation will play increasingly important roles in the future by enabling research that would not be possible for companies to undertake individually. Many examples exist, driven in large part by the FDA's Critical Path Initiative and the European Innovative Medicines Initiative, and experiences gained by early consortia will help facilitate the logistical challenges of setting up new collaborations. Within companies, innovations including the increased use of modeling and simulation throughout the drug development process, adaptive clinical trials and exploratory clinical trials have all been studied for some years, suggesting that innovation is hard, but important. Innovation is also occurring in the business models applied within individual companies to enable them to achieve “more with less”. Through adoption of new scientific approaches and business models, companies are hoping not only to refuel their pipelines but to regain the confidence of investors and the public in their ability to deliver meaningful treatments for patients at the same time as generating profits in the coming years.
The report ““Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity” examines the reasons why the pharmaceutical industry is looking for improvements in efficiency whilst acknowledging that pharmaceutical R&D remains a long and risky process. It looks in detail at precompetitive research and evaluates how the industry is pulling together to research solutions to problems that are common to all companies. Lastly, the report examines innovation in business models within the industry that aim to help the industry to achieve its mantra of “doing more with less”, which will be critical for its future success.
Scope of the report
- Detailed analysis of the reasons for the industry to be looking closely at improving efficiency
- Definition of precompetitive collaboration, analysis of areas in which precompetitive collaboration is occurring, and discussion of the expansion of this space in the future
- Explorations of the key challenges facing consortia and the factors that make them successful
- Case studies of key innovations in drug development including model-based drug development, adaptive clinical trials and exploratory clinical trials
- Detailed insights into innovation in business models, including virtual networks, open innovation and extensive academic collaborations
Explore reports available on the Drug Delivery Market @ http://www.reportsnreports.com/tags/drug-delivery-market-research.html
Contact sales(at)reportsandreports(dot)com for further information.
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebbiosimulation-technology/nanoparticles-analyzed/prweb10056514.htmView Comments and Join the Discussion!